These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 15953490

  • 1. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
    Nelson JC, Portera L, Leon AC.
    Biol Psychiatry; 2005 Jun 15; 57(12):1535-42. PubMed ID: 15953490
    [Abstract] [Full Text] [Related]

  • 2. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
    Nelson JC, Portera L, Leon AC.
    J Clin Psychiatry; 2005 Nov 15; 66(11):1409-14. PubMed ID: 16420078
    [Abstract] [Full Text] [Related]

  • 3. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
    Dubini A, Bosc M, Polin V.
    J Psychopharmacol; 1997 Nov 15; 11(4 Suppl):S17-23. PubMed ID: 9438229
    [Abstract] [Full Text] [Related]

  • 4. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
    Massana J.
    J Clin Psychiatry; 1998 Nov 15; 59 Suppl 14():8-10. PubMed ID: 9818624
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
    Taner E, Demir EY, Cosar B.
    Adv Ther; 2006 Nov 15; 23(6):974-87. PubMed ID: 17276965
    [Abstract] [Full Text] [Related]

  • 6. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M.
    J Clin Psychopharmacol; 2002 Aug 15; 22(4):393-9. PubMed ID: 12172339
    [Abstract] [Full Text] [Related]

  • 7. Clinical efficacy of reboxetine in major depression.
    Schatzberg AF.
    J Clin Psychiatry; 2000 Aug 15; 61 Suppl 10():31-8. PubMed ID: 10910015
    [Abstract] [Full Text] [Related]

  • 8. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
    Dubini A, Bosc M, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr 15; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
    [Abstract] [Full Text] [Related]

  • 9. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
    Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.
    Int Clin Psychopharmacol; 2000 Sep 15; 15(5):279-89. PubMed ID: 10993130
    [Abstract] [Full Text] [Related]

  • 10. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
    Healy D.
    Acta Psychiatr Scand Suppl; 2000 Sep 15; 402():45-51. PubMed ID: 10901159
    [Abstract] [Full Text] [Related]

  • 11. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
    Rampello L, Chiechio S, Nicoletti G, Alvano A, Vecchio I, Raffaele R, Malaguarnera M.
    Psychopharmacology (Berl); 2004 Apr 15; 173(1-2):73-8. PubMed ID: 14685645
    [Abstract] [Full Text] [Related]

  • 12. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
    Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M.
    J Clin Psychiatry; 2002 Jan 15; 63(1):31-7. PubMed ID: 11838623
    [Abstract] [Full Text] [Related]

  • 13. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
    Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R.
    J Clin Psychiatry; 1999 Jun 15; 60(6):400-6. PubMed ID: 10401920
    [Abstract] [Full Text] [Related]

  • 14. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
    Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH.
    Biol Psychiatry; 2004 Feb 01; 55(3):296-300. PubMed ID: 14744472
    [Abstract] [Full Text] [Related]

  • 15. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
    Bosc M, Dubini A, Polin V.
    Eur Neuropsychopharmacol; 1997 Apr 01; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
    [Abstract] [Full Text] [Related]

  • 16. Assessment of social functioning in depression.
    Bosc M.
    Compr Psychiatry; 2000 Apr 01; 41(1):63-9. PubMed ID: 10646621
    [Abstract] [Full Text] [Related]

  • 17. No effects of antidepressants on negative symptoms in schizophrenia.
    Hinkelmann K, Yassouridis A, Kellner M, Jahn H, Wiedemann K, Raedler TJ.
    J Clin Psychopharmacol; 2013 Oct 01; 33(5):686-90. PubMed ID: 23857309
    [Abstract] [Full Text] [Related]

  • 18. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.
    Int Clin Psychopharmacol; 2003 Sep 01; 18(5):279-84. PubMed ID: 12920388
    [Abstract] [Full Text] [Related]

  • 19. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
    Kuenzel HE, Murck H, Held K, Ziegenbein M, Steiger A.
    Pharmacopsychiatry; 2004 Sep 01; 37(5):193-5. PubMed ID: 15359374
    [Abstract] [Full Text] [Related]

  • 20. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U.
    J Clin Psychiatry; 2007 Aug 01; 68(8):1206-12. PubMed ID: 17854244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.